NYSE: IHIhuman Inc Stock
$2.08+0.02 (+0.97%)
Updated Apr 29, 2025
IH Price
$2.08
Fair Value Price
N/A
Market Cap
$108.20M
52 Week Low
$1.47
52 Week High
$3.18
P/E
8x
P/B
0.82x
P/S
0.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$126.16M
Earnings
$13.51M
Gross Margin
69.4%
Operating Margin
11.99%
Profit Margin
10.7%
Debt to Equity
0.48
Operating Cash Flow
$8M
Beta
0.66
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IH Overview
iHuman Incorporated offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, and iHuman Readers. The company also provide books, interactive materials, and smart devices that develop children's abilities in speaking, critical thinking, independent reading, and creativity. The company was founded in 1996 and is based in Beijing, China.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IH's potential to beat the market
- IH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Education
Industry Rating
A
IH
RankedUnranked of 27
RankedUnranked of 27
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.85 | A | |
| $25.22 | A | |
| $107.71 | A |
Be the first to know about important IH news, forecast changes, insider trades & much more!
IH News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IH was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IH is good value based on its earnings relative to its share price (8x), compared to the US market average (29.19x)
P/E vs Market Valuation
IH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more IH due diligence checks available for Premium users.
Valuation
IH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
8x
Industry
23.03x
Market
29.19x
IH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
IH is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
IH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.82x
Industry
2.13x
IH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IH's financial health
Profit margin
Revenue
$31.9M
Net Income
$3.6M
Profit Margin
11.4%
IH's Earnings (EBIT) of $15.13M... subscribe to Premium to read more.
Interest Coverage Financials
IH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$194.5M
Liabilities
$62.8M
Debt to equity
0.48
IH's short-term assets ($182.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IH's short-term assets ($182.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
IH's operating cash flow ($8.01M)... subscribe to Premium to read more.
Debt Coverage Financials
IH vs Education Stocks
Ihuman Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.